Melero‐Amor, A.; Romecín, P.; Iyú, D.; García‐Bernal, D.; García‐Navaro, E.; Moraleda, J.M.; García‐Estañ, J.; García‐Candel, F.; Atucha, N.M. Platelet Function and Microvesicle Generation in Patients with Hemophilia A. Clinical Case Reports 2021, 9, 1408–1415, doi:10.1002/ccr3.3788.
Melero‐Amor, A.; Romecín, P.; Iyú, D.; García‐Bernal, D.; García‐Navaro, E.; Moraleda, J.M.; García‐Estañ, J.; García‐Candel, F.; Atucha, N.M. Platelet Function and Microvesicle Generation in Patients with Hemophilia A. Clinical Case Reports 2021, 9, 1408–1415, doi:10.1002/ccr3.3788.
Melero‐Amor, A.; Romecín, P.; Iyú, D.; García‐Bernal, D.; García‐Navaro, E.; Moraleda, J.M.; García‐Estañ, J.; García‐Candel, F.; Atucha, N.M. Platelet Function and Microvesicle Generation in Patients with Hemophilia A. Clinical Case Reports 2021, 9, 1408–1415, doi:10.1002/ccr3.3788.
Melero‐Amor, A.; Romecín, P.; Iyú, D.; García‐Bernal, D.; García‐Navaro, E.; Moraleda, J.M.; García‐Estañ, J.; García‐Candel, F.; Atucha, N.M. Platelet Function and Microvesicle Generation in Patients with Hemophilia A. Clinical Case Reports 2021, 9, 1408–1415, doi:10.1002/ccr3.3788.
Abstract
Aim: In the present work we have studied the role of platelets and microvesicles in patients with severe hemophilia A (HA) treated under the regimen of prophylaxis. We have analyzed whether the administration of coagulation factor FVIII modifies this hemorrhagic phenotype in a cohort of 16 patients with diagnosis of severe HA, who were on prophylactic treatment with recombinant FVIII. Methods: Blood tests were performed before (72h without FVIII, baseline sample) and after 15 minutes of FVIII infusion. As a control group, 15 healthy subjects were studied. Platelet aggregation was determined by closure time, optical aggregation, impedance aggregation and flow cytometry. We also studied the expression of the platelet activation markers P-selectin, CD63, platelet-tissue factor, formation of platelet-leukocyte aggregates and tissue factor exposure. The total number of platelet and endothelial microvesicles were also analyzed by flow cytometry, as well as platelet cytosolic Ca2+ mobilization. Results: We found no significant differences in platelet function in patients with severe HA in prophylactic treatment before and after FVIII infusion. After FVIII administration, patients presented fewer endothelial microvesicles, indicating that the treatment does not increase one of the possible thrombotic risk markers of these patients. The total amount of plasma microvesicles and the platelet microvesicles were decreased in patients with HA compared to the control group. Conclusions: Our results do not support any effect of FVIII on platelet function in patients with severe HA treated under the regime of prophylaxis.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
*
